Strategic Initiative

Slingshot members are tracking this corporate initiative:

Sanofi (SNY) Reaches Global License Agreement to Develop ImmuNext's INX-021 in a Range of Autoimmune Diseases Including Lupus and Multiple Sclerosis

Source Link:
http://www.prnewswire.com/news-releases/sanofi-and-immunext-enter-into-agreement-to-develop-treatments-for-autoimmune-diseases-300387460.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SNY
100%
ImmuNext
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Strategic Initiative Date
Announcement Date:
Jan 09, 2017
Projected Implementation:
Q1, 2017
Relevance Tracked Until:
Q1, 2019
Related Projects Image

  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Global License Agreement, Inx-021, Autoimmune Hemolytic Diseases, Lupus, Multiple Sclerosis
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.